News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
763,403 Results
Type
Article (54270)
Company Profile (473)
Press Release (708659)
Multimedia
Podcasts (106)
Webinars (16)
Section
Business (217444)
Career Advice (2864)
Deals (37318)
Drug Delivery (121)
Drug Development (86958)
Employer Resources (184)
FDA (17224)
Job Trends (15965)
News (369149)
Policy (35654)
Tag
Academia (2921)
Academic (1)
Accelerated approval (12)
Adcomms (30)
Allergies (105)
Alliances (53402)
ALS (119)
Alzheimer's disease (1556)
Antibody-drug conjugate (ADC) (181)
Approvals (17184)
Artificial intelligence (351)
Autoimmune disease (35)
Automation (19)
Bankruptcy (391)
Best Places to Work (12290)
BIOSECURE Act (21)
Biosimilars (132)
Biotechnology (354)
Bladder cancer (100)
Brain cancer (39)
Breast cancer (388)
Cancer (3051)
Cardiovascular disease (241)
Career advice (2404)
Career pathing (33)
CAR-T (201)
CDC (38)
Cell therapy (544)
Cervical cancer (23)
Clinical research (71210)
Collaboration (1098)
Company closure (3)
Compensation (699)
Complete response letters (32)
COVID-19 (2849)
CRISPR (67)
C-suite (356)
Cystic fibrosis (119)
Data (3078)
Decentralized trials (2)
Denatured (33)
Depression (76)
Diabetes (368)
Diagnostics (6788)
Digital health (24)
Diversity (10)
Diversity, equity & inclusion (46)
Drug discovery (152)
Drug pricing (145)
Drug shortages (31)
Duchenne muscular dystrophy (134)
Earnings (90232)
Editorial (47)
Employer branding (23)
Employer resources (159)
Events (122287)
Executive appointments (904)
FDA (18931)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (992)
Gene editing (145)
Generative AI (27)
Gene therapy (424)
GLP-1 (897)
Government (4989)
Grass and pollen (6)
Guidances (181)
Healthcare (20216)
HIV (43)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (179)
Immuno-oncology (11)
Indications (40)
Infectious disease (3038)
Inflammatory bowel disease (163)
Inflation Reduction Act (13)
Influenza (69)
Intellectual property (124)
Interviews (555)
IPO (17202)
IRA (53)
Job creations (4104)
Job search strategy (1978)
Kidney cancer (15)
Labor market (52)
Layoffs (564)
Leadership (25)
Legal (8762)
Liver cancer (85)
Longevity (12)
Lung cancer (429)
Lymphoma (214)
Machine learning (11)
Management (62)
Manufacturing (416)
MASH (98)
Medical device (14150)
Medtech (14155)
Mergers & acquisitions (20835)
Metabolic disorders (933)
Multiple sclerosis (103)
NASH (23)
Neurodegenerative disease (137)
Neuropsychiatric disorders (41)
Neuroscience (2299)
NextGen: Class of 2025 (7249)
Non-profit (4908)
Now hiring (47)
Obesity (476)
Opinion (275)
Ovarian cancer (104)
Pain (118)
Pancreatic cancer (125)
Parkinson's disease (198)
Partnered (22)
Patents (315)
Patient recruitment (172)
Peanut (55)
People (62835)
Pharmaceutical (89)
Pharmacy benefit managers (23)
Phase I (22201)
Phase II (31257)
Phase III (23277)
Pipeline (1687)
Policy (233)
Postmarket research (2931)
Preclinical (9591)
Press Release (70)
Prostate cancer (149)
Psychedelics (46)
Radiopharmaceuticals (274)
Rare diseases (514)
Real estate (6459)
Recruiting (73)
Regulatory (24607)
Reports (51)
Research institute (2591)
Resumes & cover letters (454)
Rett syndrome (10)
RNA editing (10)
RSV (54)
Schizophrenia (97)
Series A (170)
Series B (117)
Service/supplier (15)
Sickle cell disease (67)
Special edition (21)
Spinal muscular atrophy (160)
Sponsored (35)
Startups (3945)
State (2)
Stomach cancer (17)
Supply chain (81)
Tariffs (63)
The Weekly (71)
Vaccines (877)
Venture capital (58)
Weight loss (310)
Women's health (50)
Worklife (19)
Date
Today (86)
Last 7 days (375)
Last 30 days (1922)
Last 365 days (32768)
2025 (17703)
2024 (37125)
2023 (41888)
2022 (53212)
2021 (57874)
2020 (56596)
2019 (49834)
2018 (37692)
2017 (34712)
2016 (34538)
2015 (40637)
2014 (34685)
2013 (29997)
2012 (32065)
2011 (32509)
2010 (30801)
Location
Africa (918)
Alabama (69)
Alaska (7)
Arizona (260)
Arkansas (14)
Asia (43219)
Australia (7819)
California (7684)
Canada (2408)
China (714)
Colorado (332)
Connecticut (336)
Delaware (198)
Europe (96715)
Florida (1135)
Georgia (254)
Hawaii (1)
Idaho (63)
Illinois (689)
India (30)
Indiana (372)
Iowa (18)
Japan (236)
Kansas (114)
Kentucky (32)
Louisiana (15)
Maine (64)
Maryland (1074)
Massachusetts (5804)
Michigan (255)
Minnesota (471)
Mississippi (3)
Missouri (98)
Montana (31)
Nebraska (25)
Nevada (81)
New Hampshire (72)
New Jersey (2146)
New Mexico (31)
New York (2153)
North Carolina (1196)
North Dakota (9)
Northern California (3348)
Ohio (242)
Oklahoma (16)
Oregon (40)
Pennsylvania (1645)
Puerto Rico (18)
Rhode Island (39)
South America (1295)
South Carolina (35)
South Dakota (1)
Southern California (2862)
Tennessee (129)
Texas (1161)
United States (28722)
Utah (227)
Virginia (197)
Washington D.C. (79)
Washington State (667)
West Virginia (4)
Wisconsin (72)
763,403 Results for "cellectar biosciences formerly known as novelos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
June 26, 2025
·
5 min read
Press Releases
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
July 2, 2025
·
5 min read
Press Releases
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 14, 2025
·
8 min read
Press Releases
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
June 6, 2025
·
4 min read
Press Releases
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
June 24, 2025
·
6 min read
Press Releases
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
June 11, 2025
·
6 min read
Press Releases
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
May 8, 2025
·
2 min read
Press Releases
Cellectar Biosciences to Present at the 37th Annual Roth Conference
March 12, 2025
·
2 min read
Press Releases
Cellectar Announces Plan to Explore Strategic Alternatives
April 30, 2025
·
4 min read
Press Releases
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
March 13, 2025
·
11 min read
1 of 76,341
Next
